- The investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab (BAN2401) met the primary endpoint and all secondary endpoints of a global phase 3 trial conducted in patients with mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain, Eisai and Biogen announced in a news release. The Clarity AD study results will be presented in late Nov. at the Clinical Trials on Alzheimer’s Congress and published in a peer-reviewed medical journal, the companies said. Eisai plans to discuss these data with regulatory authorities in the U.S., Japan, and Europe with the aim of filing for traditional approval in the U.S. and for marketing authorization applications in Japan and Europe by Mar. 31, 2023.
- CDC yesterday released the 2021 data for its important Behavioral Risk Factor Surveillance System (BRFSS). The agency said BRFSS provides a sound basis for understanding health issues in states, assessing and maintaining public health programs, and making progress on improving health and reducing health disparities. The prevalence and trends tool offers fast access to a large portion of the 2021 data set and can be a helpful resource to reporters, students, public-health officials, and decision-makers. The tool is updated every year.
- A large international study has confirmed the findings of a previous U.S. study that linked COVID-19 vaccination with an average increase in menstrual cycle length of less than 1 day, NIH said yesterday. The increase was not associated with any change in the number of days of menses. The NIH-funded study included data from nearly 20,000 people from Canada, U.K., U.S., Europe, and other parts of the world who received any of 9 vaccines. For most study participants, the increase resolved in the cycle following vaccination. The study is being published in BMJ Medicine.
